Hospira appoints Richard Davies as chief commercial officer

pharmafile | February 8, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |  Hospira, Richard Davies 

Hospira has announced Richard Davies as its senior vice president and chief commercial officer.

In this role, he will be responsible for developing and executing Hospira’s global commercial strategies and delivering profitable revenue growth across the company’s product portfolio.

Davies will serve as a member of Hospira’s senior leadership team, reporting to F. Michael Ball, chief executive. 

“From catalysing growth in well-established products to architecting bold new strategies for emerging markets, Richard has a track record of unparalleled success in the healthcare industry,” said Mr. Ball.

Advertisement

Davies brings to Hospira more than 20 years of diverse strategic and operational experience gained through a variety of commercial management positions and across a range of products and technologies.

Most recently, he served as vice president and general manager, Japan, Asia Pacific and Latin America, for Amgen, where he was responsible for establishing Amgen’s business in the region as well as supporting its strategy development for emerging markets overall. During his eight years at Amgen, he led the company’s commercial organizations in Central/Eastern Europe and Australia, and also served as vice president of U.S. sales for the immunology franchise.

Prior to joining Amgen, Mr. Davies spent 13 years at Eli Lilly and Company in increasing roles of commercial responsibility, including general country management.

Related Content

Hospira in US-wide recall of product due to contamination

Hospira, a company owned by Pfizer, has been forced to recall a batch of injectable …

ICU Medical to acquire Pfizer’s global infusion therapy business in $1 billion deal

The $1 billion deal that will take place as ICU Medical Inc. take over Pfizer’s …

Hospira logo

Pfizer may sell off Hospira unit for $2 billion

Pfizer is reportedly considering selling Hospira’s infusion pump business for around $2 billion, having acquired …

The Gateway to Local Adoption Series

Latest content